Licensing · Global (LMICs) · Announced 23 Dec 2025
Biocon → Ajanta Pharma
Biocon out-licensed its generic semaglutide to Ajanta Pharma for 26 countries across Africa, the Middle East and Central Asia, exclusive in 23 and semi-exclusive in three; launches are expected from late 2026 or early 2027.
Parties: Biocon (India) → Ajanta Pharma (India)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- 26 countries across Africa, the Middle East and Central Asia (exclusive in 23, semi-exclusive in 3; countries not named)
- Therapeutic area
- Metabolic / Diabetes
- Asset
- semaglutide
- Announced
- 23 Dec 2025
Our analysis
Why this matters
Ajanta Pharma announced on 23 December 2025, after market hours, an in-licensing agreement with Biocon for Biocon's semaglutide, the GLP-1 molecule behind Ozempic and Wegovy. Biocon supplies the product and Ajanta markets it in 26 countries across Africa, the Middle East and Central Asia: exclusively in 23 and semi-exclusively in three. The countries were not named and no financial terms were disclosed.
Ajanta said it would commercialise after regulatory approvals, which it expected in late 2026 or early 2027. Business Standard reported that Novo Nordisk's product patent on semaglutide expires in most of these markets in March 2026. In November 2026 Business Standard added that Ajanta expects commercial sales only from its FY28 (April 2027 to March 2028).
The full analysis is free to read with a work email on this page.
Source: Business Standard